Redeye has started to follow Immunicum. Read the initial analysis in Swedish here: Analysis.
Immunicum’s patent application regarding the Company’s core-technology for therapeutic cancer vaccination using allogeneic dendritic cells is being approved in the U.S.
The United States Patent and Trademark Office (USPTO), has issued a notice of allowance regarding patent application 11/603,819… Read more
The first patient in Immunicum’s clinical phase I/II-study in primary liver cancer today received the initial dose of… Read more
The Regional Ethical Review Board approves start of Immunicum’s planned liver cancer vaccine study.
The magazine “Ny Teknik” releases its new issue and features Immunicum.
IMMUNICUM® is registered as a trade mark in the EU at OHIM (Office for Harmonization in the Internal Market).